FDA Advisory Panel Votes Down Cytokinetics’ Heart Failure Candidate

Cytokinetics’ omecamtiv mecarbil received an 8-3 thumbs-down from the FDA’s Cardiovascular and Renal Drugs Advisory Committee, with the majority agreeing that the risks of the myosin activator outweigh its benefits for treating patients with heart failure and reduced ejection fraction.
Source: Drug Industry Daily